<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01850823</url>
  </required_header>
  <id_info>
    <org_study_id>71209805</org_study_id>
    <nct_id>NCT01850823</nct_id>
  </id_info>
  <brief_title>Clinical Equivalence Study of Mometasone Nasal Spray</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actavis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Watson Laboratories, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Actavis Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Site Study to Compare&#xD;
      the Clinical Equivalence of Mometasone Nasal Spray (Watson Laboratories, Inc) with NASONEX®&#xD;
      Nasal Spray (Schering Corporation) in the Relief of the Signs and Symptoms of Seasonal&#xD;
      Allergic Rhinitis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Average AM/PM Reflective Total Nasal Symptom Score (rTNSS) Over Days 1 to 14.</measure>
    <time_frame>Twice daily from Baseline to 2 weeks</time_frame>
    <description>The Total Nasal Symptom Score Scale was used. Patients rated each of the following four symptoms on a scale from 0 to 3 : Nasal Congestion, Runny Nose, Sneezing, and Itchy Nose. Measurements were taken twice daily approximately 12 hours apart.&#xD;
0= No symptom&#xD;
Mild symptoms (sign/symptom present, minimal awareness, easily tolerated)&#xD;
Moderate symptom (definite awareness of sign/symptom, bothersome but tolerable)&#xD;
Severe symptom (sign/symptom hard to tolerate, causes interference with daily activities and/or sleeping)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Superiority of Active Treatment Arms Over Placebo</measure>
    <time_frame>Twice daily from Baseline to 2 weeks</time_frame>
    <description>Superiority analysis of Change From Baseline in rTNSS for both active arms compared to placebo arm. The Total Nasal Symptom Score Scale was used. Patients rated each of the following four symptoms on a scale from 0 to 3: Nasal Congestion, Runny Nose, Sneezing, and Itchy Nose twice daily approximately 12 hours apart.&#xD;
0= No symptom&#xD;
Mild symptoms (sign/symptom present, minimal awareness, easily tolerated)&#xD;
Moderate symptom (definite awareness of sign/symptom, bothersome but tolerable)&#xD;
Severe symptom (sign/symptom hard to tolerate, causes interference with daily activities and/or sleeping)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">880</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NASONEX® Nasal Spray (Schering Corporation)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mometasone Nasal spray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mometasone Nasal Spray (Watson Laboratories, Inc)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mometasone Nasal spray</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone Nasal Spray</intervention_name>
    <arm_group_label>NASONEX® Nasal Spray (Schering Corporation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone nasal spray</intervention_name>
    <arm_group_label>Mometasone Nasal Spray (Watson Laboratories, Inc)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or non-pregnant non-lactating female&#xD;
&#xD;
          -  12 years of age or older&#xD;
&#xD;
          -  Signed informed consent form, which meets all criteria of current FDA regulations. For&#xD;
             patients under the age of majority in the state the study is being conducted (18 years&#xD;
             in most states) the parent or legal guardian should sign the consent form and the&#xD;
             child will be required to sign a patient &quot;assent&quot; form that will be written in such a&#xD;
             way as to be understandable to a child.&#xD;
&#xD;
          -  If female and of child-bearing potential, have a negative urine pregnancy test and is&#xD;
             prepared to abstain from sexual intercourse or use a reliable method of contraception&#xD;
             during the study (e.g., condom with spermicide, IUD, oral, injected, transdermal or&#xD;
             implanted hormonal contraceptives). In order for hormonal birth control to be&#xD;
             considered a reliable method the patient must have been on their regimen for at least&#xD;
             28 days.&#xD;
&#xD;
          -  Documented positive allergic skin test, performed within the previous 12 months, to&#xD;
             one or more of the allergens in season at the time the study is being conducted.&#xD;
&#xD;
          -  A minimum of two consecutive years of previous history of seasonal allergic rhinitis&#xD;
             to the pollen/allergen in season at the time the study is being conducted.&#xD;
&#xD;
          -  A score of at least 6 on the reflective Total Nasal Symptom Score (rTNSS) and a&#xD;
             minimum score of at least 2 for &quot;nasal congestion&quot; and a minimum score of at least 2&#xD;
             for one of the remaining 3 symptoms (see Appendix A) representing the 12 hours prior&#xD;
             to the screening visit.&#xD;
&#xD;
          -  An average composite score of at least 6 on the reflective Total Nasal Symptom Score&#xD;
             (rTNSS) and a minimum score of at least 2 for &quot;nasal congestion&quot; and a minimum score&#xD;
             of at least 2 for one of the remaining 3 symptoms (see Appendix A) representing the&#xD;
             last 3 days of the 7-day placebo run-in period before the randomization visit and the&#xD;
             morning of the first day of the randomization visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Under 12 years of age.&#xD;
&#xD;
          -  Females who are pregnant, lactating or likely to become pregnant during the study.&#xD;
&#xD;
          -  Negative or lack of documented skin allergen test (performed within the previous 12&#xD;
             months) to at least one of the allergens in season at the time the study is being&#xD;
             conducted. The results of all positive skin allergen test results should be reported.&#xD;
&#xD;
          -  Patients who suffer from chronic signs and symptoms of Perennial Allergic Rhinitis&#xD;
             (PAR) should be excluded from the study unless the Investigator assesses that the&#xD;
             patient's current signs and symptoms are a clear exacerbation of Seasonal Allergic&#xD;
             Rhinitis (SAR) rather than chronic PAR.&#xD;
&#xD;
          -  Patients who suffer only from perennial allergic rhinitis or seasonal allergic&#xD;
             rhinitis to a different allergen than that in season at the time the study is&#xD;
             conducted.&#xD;
&#xD;
          -  Previous history of less than 2 years of seasonal allergic rhinitis to the&#xD;
             pollen/allergen in season at the time the study is being conducted.&#xD;
&#xD;
          -  A total score of less than 6 on the reflective Total Nasal Symptom Score (rTNSS) or a&#xD;
             score less than 2 for &quot;nasal congestion&quot; or a score less than 2 for all 3 of the&#xD;
             remaining symptoms (see Appendix A). Any patient who meets the minimum rTNSS&#xD;
             requirements at the start of the placebo lead-in period but no longer meets the&#xD;
             requirements prior to the randomized active treatment period of the study cannot&#xD;
             continue in the active treatment period.&#xD;
&#xD;
          -  History of asthma over the previous two years that required chronic therapy.&#xD;
             Occasional acute or mild exercise induced asthma will be allowable on the condition&#xD;
             that the treatment of the attacks is restricted to beta-agonists only.&#xD;
&#xD;
          -  Patients with nasal conditions, including infectious rhinitis, rhinitis medicamentosa&#xD;
             or atrophic rhinitis.&#xD;
&#xD;
          -  Clinically significant nasal deformity (e.g. significantly deformed septum, nasal&#xD;
             polyps or ulcers) or any recent nasal surgery or trauma that has not completely&#xD;
             healed.&#xD;
&#xD;
          -  Sinus infection within the previous 30 days or history of re-occurring sinus&#xD;
             infections.&#xD;
&#xD;
          -  Patient has started immunotherapy (including topical or desensitization therapy) or&#xD;
             changed their dose of immunotherapy within 30 days of the first placebo lead-in dose&#xD;
             or is likely to have to start immunotherapy, or change their current dose during the&#xD;
             study.&#xD;
&#xD;
          -  Treatment for oral Candidiasis within 30 days of starting the study or a current oral&#xD;
             Candidiasis infection.&#xD;
&#xD;
          -  Upper respiratory tract infection within the previous 30 days.&#xD;
&#xD;
          -  Patients with a history of tuberculosis.&#xD;
&#xD;
          -  Patients with the presence of glaucoma, cataracts, ocular herpes simplex,&#xD;
             conjunctivitis or other eye infection not related to the diagnosis of SAR within 14&#xD;
             days of enrollment.&#xD;
&#xD;
          -  The patient has had recent exposure (30 days) or was at risk of being exposed to&#xD;
             chicken pox or measles.&#xD;
&#xD;
          -  Patients with any untreated fungal, bacterial, systemic viral infections within the&#xD;
             previous 30 days.&#xD;
&#xD;
          -  Use of any ophthalmic steroids within 14 days or nasal, inhaled or systemic steroids&#xD;
             within 30 days of the study start. Super or high potency topical steroids should not&#xD;
             be used during the study. The use of low potency topical corticosteroids (e.g. OTC 1%&#xD;
             hydrocortisone) will be allowed. The use of hormonal contraceptives or hormone&#xD;
             replacement therapy is allowed, on condition the patient has been on a stable dosing&#xD;
             regimen for at least 28 days prior to the start of the study and remains on the same&#xD;
             dosing regimen during the study.&#xD;
&#xD;
          -  Use of intranasal or systemic second-generation anti-histamines (e.g. fexofenadine,&#xD;
             loratadine, desloratadine, cetirizine) within 10 days of enrollment.&#xD;
&#xD;
          -  Use of intranasal cromolyn within 14 days of enrollment.&#xD;
&#xD;
          -  Use of intranasal or systemic first-generation anti-histamines, leukotriene receptor&#xD;
             antagonists (montelukast) or other nasal decongestants within 3 days of enrollment.&#xD;
&#xD;
          -  Use of any tricyclic anti-depressant within 30 days of enrollment.&#xD;
&#xD;
          -  Patients with attention-deficit disorder being treated with methylphenidate containing&#xD;
             products that have not been on a stable dosing regimen for at least the 30 previous&#xD;
             days and who cannot remain on the same dosing regimen throughout the study.&#xD;
&#xD;
          -  Desensitization therapy to the seasonal allergen that is causing the patients allergic&#xD;
             rhinitis within the previous 6 months.&#xD;
&#xD;
          -  Previous SAR and/or PAR that has proven unresponsive to steroid therapy.&#xD;
&#xD;
          -  Any known hypersensitivity to mometasone, other steroids or any of the components of&#xD;
             the study nasal spray.&#xD;
&#xD;
          -  Significant history or current evidence of chronic infectious disease, system&#xD;
             disorder, organ disorder or other medical condition that in the Investigator's opinion&#xD;
             would place the study patient at undue risk by participating or could jeopardize the&#xD;
             integrity of the study evaluations.&#xD;
&#xD;
          -  Receipt of any drug as part of a research study within 30 days prior to the first&#xD;
             placebo lead-in dose.&#xD;
&#xD;
          -  Planned travel outside of the local area for more than 2 consecutive days or 3 days in&#xD;
             total, during the patient's participation in the study.&#xD;
&#xD;
          -  Previous participation in this study.&#xD;
&#xD;
          -  The patient has a history of non-compliance with medication regimens or treatment&#xD;
             protocols in previous clinical studies.&#xD;
&#xD;
          -  The patient is a member of the investigational study staff or a member of the family&#xD;
             of the investigational study staff.&#xD;
&#xD;
          -  The patient currently smokes cigarettes, cigars, and/or pipes and is a heavy smoker&#xD;
             (for example, on average more than 10 cigarettes per day).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Investigator site 18</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 1</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 3</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 19</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 24</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 22</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 23</name>
      <address>
        <city>Skillman</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 2</name>
      <address>
        <city>Corning</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 9</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 20</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 25</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 21</name>
      <address>
        <city>Sylvania</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 16</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 10</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 12</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 6</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 11</name>
      <address>
        <city>Kerrville</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 7</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 13</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 14</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 5</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 8</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 4</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 15</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 17</name>
      <address>
        <city>Greenfield</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 6, 2013</study_first_submitted>
  <study_first_submitted_qc>May 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2013</study_first_posted>
  <results_first_submitted>April 8, 2020</results_first_submitted>
  <results_first_submitted_qc>August 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 19, 2020</results_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mometasone Furoate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Randomized subjects in active treatment.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo vehicle nasal spray (no active ingredients) Dose = 4 total actuations in alternating nostrils</description>
        </group>
        <group group_id="P2">
          <title>NASONEX® Nasal Spray (Schering Corporation)</title>
          <description>Mometasone Nasal spray, 50 mcg per actuation Dose = 4 total actuations in alternating nostrils (total dose = 200 mcg)</description>
        </group>
        <group group_id="P3">
          <title>Mometasone Nasal Spray (Watson Laboratories, Inc)</title>
          <description>Mometasone Nasal spray, 50 mcg per actuation Dose = 4 total actuations in alternating nostrils (total dose = 200 mcg)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="175"/>
                <participants group_id="P2" count="350"/>
                <participants group_id="P3" count="355"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="172"/>
                <participants group_id="P2" count="347"/>
                <participants group_id="P3" count="345"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Early Visit Window</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Enrolled in Error</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Restricted Medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Significant worstening of SAR</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized Subjects</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo vehicle nasal spray (no active ingredients) Dose = 4 total actuations in alternating nostrils</description>
        </group>
        <group group_id="B2">
          <title>NASONEX® Nasal Spray (Schering Corporation)</title>
          <description>Mometasone Nasal spray, 50 mcg per actuation Dose = 4 total actuations in alternating nostrils (total dose = 200 mcg)</description>
        </group>
        <group group_id="B3">
          <title>Mometasone Nasal Spray (Watson Laboratories, Inc)</title>
          <description>Mometasone Nasal spray, 50 mcg per actuation Dose = 4 total actuations in alternating nostrils (total dose = 200 mcg)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="175"/>
            <count group_id="B2" value="350"/>
            <count group_id="B3" value="355"/>
            <count group_id="B4" value="880"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.31" spread="14.45"/>
                    <measurement group_id="B2" value="38.70" spread="14.45"/>
                    <measurement group_id="B3" value="38.80" spread="14.18"/>
                    <measurement group_id="B4" value="39.00" spread="14.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="243"/>
                    <measurement group_id="B3" value="216"/>
                    <measurement group_id="B4" value="585"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="139"/>
                    <measurement group_id="B4" value="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="259"/>
                    <measurement group_id="B3" value="276"/>
                    <measurement group_id="B4" value="658"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian/Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tobacco Use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Have used tobacco</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Have not use tobacco</title>
                  <measurement_list>
                    <measurement group_id="B1" value="168"/>
                    <measurement group_id="B2" value="336"/>
                    <measurement group_id="B3" value="342"/>
                    <measurement group_id="B4" value="846"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary Allergen</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Tree</title>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="234"/>
                    <measurement group_id="B3" value="231"/>
                    <measurement group_id="B4" value="575"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Multi-Allergen</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="119"/>
                    <measurement group_id="B4" value="297"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grass</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Average AM/PM Reflective Total Nasal Symptom Score (rTNSS) Over Days 1 to 14.</title>
        <description>The Total Nasal Symptom Score Scale was used. Patients rated each of the following four symptoms on a scale from 0 to 3 : Nasal Congestion, Runny Nose, Sneezing, and Itchy Nose. Measurements were taken twice daily approximately 12 hours apart.&#xD;
0= No symptom&#xD;
Mild symptoms (sign/symptom present, minimal awareness, easily tolerated)&#xD;
Moderate symptom (definite awareness of sign/symptom, bothersome but tolerable)&#xD;
Severe symptom (sign/symptom hard to tolerate, causes interference with daily activities and/or sleeping)</description>
        <time_frame>Twice daily from Baseline to 2 weeks</time_frame>
        <population>Per Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>NASONEX® Nasal Spray (Schering Corporation)</title>
            <description>Mometasone Nasal spray, 50 mcg per acuation Dose = 4 total actuations in alternating nostrils (total dose = 200 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Mometasone Nasal Spray (Watson Laboratories, Inc)</title>
            <description>Mometasone Nasal spray, 50 mcg per actuation Dose = 4 total actuations in alternating nostrils (total dose = 200 mcg)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average AM/PM Reflective Total Nasal Symptom Score (rTNSS) Over Days 1 to 14.</title>
          <description>The Total Nasal Symptom Score Scale was used. Patients rated each of the following four symptoms on a scale from 0 to 3 : Nasal Congestion, Runny Nose, Sneezing, and Itchy Nose. Measurements were taken twice daily approximately 12 hours apart.&#xD;
0= No symptom&#xD;
Mild symptoms (sign/symptom present, minimal awareness, easily tolerated)&#xD;
Moderate symptom (definite awareness of sign/symptom, bothersome but tolerable)&#xD;
Severe symptom (sign/symptom hard to tolerate, causes interference with daily activities and/or sleeping)</description>
          <population>Per Protocol Population</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="346"/>
                <count group_id="O2" value="342"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.861" spread="2.186"/>
                    <measurement group_id="O2" value="1.600" spread="2.223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Conducted on Per Protocol Population</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence based on Test/Reference Ratio and 90% confidence interval (as per OGD guidance)</non_inferiority_desc>
            <param_type>Ratio Test/Reference LS Mean</param_type>
            <param_value>114.723</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.077</ci_lower_limit>
            <ci_upper_limit>134.286</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Superiority of Active Treatment Arms Over Placebo</title>
        <description>Superiority analysis of Change From Baseline in rTNSS for both active arms compared to placebo arm. The Total Nasal Symptom Score Scale was used. Patients rated each of the following four symptoms on a scale from 0 to 3: Nasal Congestion, Runny Nose, Sneezing, and Itchy Nose twice daily approximately 12 hours apart.&#xD;
0= No symptom&#xD;
Mild symptoms (sign/symptom present, minimal awareness, easily tolerated)&#xD;
Moderate symptom (definite awareness of sign/symptom, bothersome but tolerable)&#xD;
Severe symptom (sign/symptom hard to tolerate, causes interference with daily activities and/or sleeping)</description>
        <time_frame>Twice daily from Baseline to 2 weeks</time_frame>
        <population>Intent to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo vehicle nasal spray (no active ingredients) Dose = 4 total actuations in alternating nostrils</description>
          </group>
          <group group_id="O2">
            <title>NASONEX® Nasal Spray (Schering Corporation)</title>
            <description>Mometasone Nasal spray, 50 mcg per actuation Dose = 4 total actuations in alternating nostrils (total dose = 200 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Mometasone Nasal Spray (Watson Laboratories, Inc)</title>
            <description>Mometasone Nasal spray, 50 mcg per actuation Dose = 4 total actuations in alternating nostrils (total dose = 200 mcg)</description>
          </group>
        </group_list>
        <measure>
          <title>Superiority of Active Treatment Arms Over Placebo</title>
          <description>Superiority analysis of Change From Baseline in rTNSS for both active arms compared to placebo arm. The Total Nasal Symptom Score Scale was used. Patients rated each of the following four symptoms on a scale from 0 to 3: Nasal Congestion, Runny Nose, Sneezing, and Itchy Nose twice daily approximately 12 hours apart.&#xD;
0= No symptom&#xD;
Mild symptoms (sign/symptom present, minimal awareness, easily tolerated)&#xD;
Moderate symptom (definite awareness of sign/symptom, bothersome but tolerable)&#xD;
Severe symptom (sign/symptom hard to tolerate, causes interference with daily activities and/or sleeping)</description>
          <population>Intent to treat.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="348"/>
                <count group_id="O3" value="354"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.898" spread="1.762"/>
                    <measurement group_id="O2" value="1.609" spread="2.225"/>
                    <measurement group_id="O3" value="1.863" spread="2.191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The superiority of treatment over the placebo will be concluded if the treatment's mean change from baseline is statistically significantly greater (p&lt;0.05, 2-sided) than that of the placebo in the ANCOVA based on the treatment and placebo results. The superiority of Test and Reference treatments over the placebo will be evaluated identically in a separate ANCOVA.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The superiority of treatment over the placebo will be concluded if the treatment's mean change from baseline is statistically significantly greater (p&lt;0.05, 2-sided) than that of the placebo in the ANCOVA based on the treatment and placebo results. The superiority of Test and Reference treatments over the placebo will be evaluated identically in a separate ANCOVA.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were collected from ICF signature until end of study (~1 month in duration).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo vehicle nasal spray (no active ingredients) Dose = 4 total actuations in alternating nostrils</description>
        </group>
        <group group_id="E2">
          <title>NASONEX® Nasal Spray (Schering Corporation)</title>
          <description>Mometasone Nasal spray, 50 mcg per actuation Dose = 4 total actuations in alternating nostrils (total dose = 200 mcg)</description>
        </group>
        <group group_id="E3">
          <title>Mometasone Nasal Spray (Watson Laboratories, Inc)</title>
          <description>Mometasone Nasal spray, 50 mcg per actuation Dose = 4 total actuations in alternating nostrils (total dose = 200 mcg)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="350"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthryroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Eye Irritation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Eye Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Ocular Hyperaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Xerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Seasonal Allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Ear Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Herpes Simplex</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Viral Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Sinus Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="350"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Throat Irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="175"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pulmonary Congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director, PD/CE Studies</name_or_title>
      <organization>Teva Pharmaceuticals Inc., USA</organization>
      <phone>1-888-483-8279</phone>
      <email>usmedinfo@tevapharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

